DINAMIQS

What DINAMIQS does

DINAMIQS is a Swiss contract development and manufacturing organization (CDMO) founded in 2022 and headquartered at Bio-Technopark in Schlieren (Zurich), specializing in viral vector manufacturing for cell and gene therapies. The company originated from the Vectorology team of DiNAQOR AG and operates as a 95%-owned subsidiary of Siegfried Holding AG, the publicly listed Swiss CDMO. DINAMIQS produces recombinant adeno-associated virus (AAV) and lentivirus (rLV) vectors using proprietary suspension-based cell culture processes built on ExcellGene's HEKExpress and HEK2Express cell lines, supported by an advanced analytical platform (digital PCR, mass photometry, light scattering, long-read nanopore sequencing).

The company offers an integrated service portfolio spanning genome optimization, capsid optimization, upstream and downstream process development, GMP manufacturing at up to 1,000L scale, analytical and QC services, and aseptic drug product filling. Its 2,500m² cGMP manufacturing facility, inaugurated in September 2025, and new R&D and QC laboratories opened in November 2024, consolidate clinical and commercial viral vector production under one roof. DINAMIQS received its Swissmedic manufacturing and testing license in April 2026, making it the first fully integrated viral vector CDMO licensed in Switzerland; Switzerland's mutual recognition agreements with the EMA and FDA extend regulatory acceptance of its products into Europe and the United States.

DINAMIQS generates revenue through project-based CDMO contracts covering process development, GMP manufacturing, and analytics for genetic medicine developers across the Americas, Europe, and Asia-Pacific. The company targets three customer segments—emerging biotechs (primary), cell and gene therapy developers (primary use case), and large pharmaceutical companies (secondary)—and conducts direct B2B sales through a regionally distributed business development team supported by conference participation at ASGCT, ESGCT, JP Morgan Healthcare Conference, and other industry events. Named clients include DiNAQOR, Combigene, SEAL Therapeutics, an APAC-based biotech, and a UK-based biotech. The company employs approximately 50 scientific and GMP staff and operates with Siegfried's global network of 13 sites for downstream sterile drug product manufacturing.

Name

DINAMIQS

Legal name

DINAMIQS

Website

https://dinamiqs.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

DINAMIQS is a Swiss CDMO specializing in contract development and GMP manufacturing of AAV and lentiviral vectors for cell and gene therapy developers. It offers end-to-end viral vector services from genome optimization through aseptic drug product filling at its 2,500m² cGMP facility in Zurich.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Contract Manufacturing (Viral Vector CDMO)

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Gene Therapy CDMO (Viral Vector Manufacturing) (HLAGAGAB)

akta.pro secondary industries

Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE), Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral) (HLAAAKAD), Gene Therapy Analytical Testing & QC (potency, vg/ddPCR, infectivity, RCL/RCA) (HLAAACAK), Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN)

Keywords

• Viral vector CDMO
• AAV manufacturing
• Lentivirus production
• Gene therapy services
• Contract biomanufacturing

Headquarters

HQ city

Schlieren

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Infrastructure, Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. CDMO Manufacturing Services: Contract Development and Manufacturing Organization providing viral vector manufacturing services including process development, GMP manufacturing, quality control, and analytics for genetic medicine companies. Revenue is generated through project-based contracts and service agreements for clinical and commercial supply.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Core offering

DINAMIQS is a science-driven Contract Development and Manufacturing Organization (CDMO) providing end-to-end viral vector services for AAV and Lentivirus production. Its offering spans genome and capsid optimization, upstream and downstream process development, cGMP manufacturing from clinical to commercial scale (up to 1,000L), advanced analytical characterization, and aseptic fill-finish — all integrated under a single Swissmedic-licensed facility in Zurich with access to Siegfried's global manufacturing network.

Product overview

DINAMIQS is a science-driven Contract Development and Manufacturing Organization (CDMO) offering end-to-end viral vector solutions. The company provides an integrated portfolio of services including Genome Optimization, Capsid Optimization, Process Development, GMP Manufacturing, Analytical Services, and Fill and Finish capabilities. Their manufacturing platform utilizes ExcellGene's HEKExpress and HEK2Express cell line technologies for recombinant AAV and Lentivirus production. Services range from early R&D (up to 50L scale) through clinical and commercial manufacturing (up to 1,000L scale) at their cGMP facility in Zurich, with access to Siegfried's global manufacturing network for sterile drug product filling.

Differentiator

Problem solved

Functional benefit

Products and services

• Viral Vector Manufacturing (AAV and Lentivirus)

Quantifiable outcome

• Produced more than 300 preclinical batches of Adeno-Associated and Lenti Virus vectors
• +3 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core, flagship, minor and supporting.

• ExcellGenecoreTechnology or Integration · 11 December 2025Licensing agreement for ExcellGene's HEKExpress® and HEK2Express® suspension cell line technologies for GMP manufacturing of recombinant Adeno-associated virus (rAAV) and Lentivirus (rLV) vectors for in-vivo and ex-vivo gene therapies. ExcellGene is a Swiss biotechnology company specializing in high-performance mammalian cell lines and bioprocesses.
• SEAL TherapeuticscoreStrategic or Co-development Partner · 29 September 2025Strategic collaboration to support development and manufacturing of a gene therapy for LAMA2 related muscular dystrophy. SEAL Therapeutics, a spin-off from the Biozentrum of the University of Basel, is developing an innovative gene therapy designed to address functional defects that cause severe childhood-onset muscular dystrophy with no current treatment option. DINAMIQS experts will scale up production to enable transition from laboratory research toward potential patient treatment.
• Siegfried Holding AGflagshipOthers · 24 May 2023Siegfried acquired a 95% stake in DINAMIQS in 2023, bringing DINAMIQS' capabilities to commercial scale and establishing it as a best-in-class biotech CDMO for cell and gene therapies. Siegfried is building state-of-the-art GMP facilities and provides access to its global network of 13 sites across US, Europe, and China, including fill-finish capabilities.
• Magic Horizon ConsortiumminorStrategic or Co-development Partner · 1 January 2023DINAMIQS is a member of the MAGIC Horizon consortium focused on accelerating the development of gene therapies for muscular dystrophies. This EU-funded project brings together academic and industry partners to advance muscular dystrophy treatments.
• Capsid Optimization PartnerssupportingTechnology or Integration · 1 January 2023DINAMIQS works with established partners dedicated to capsid optimization, including AI approaches, to support genome and capsid optimization services for customers.

Scale indicators6 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Yposkesi: Yposkesi is a French CDMO specializing in AAV and lentiviral vector GMP manufacturing for gene therapy, founded by Généthon and AFM-Téléthon. Direct peer in viral vector CDMO with comparable European customer base and modality focus.
• VIVEbiotech (Viralgen): VIVEbiotech is a Spain-based CDMO specialized in lentiviral and AAV vector manufacturing for gene and cell therapy, with GMP capabilities serving European and global gene therapy developers — comparable modality, services, and geographic reach to DINAMIQS.
• Andelyn Biosciences: Andelyn is a viral vector CDMO spun out of Nationwide Children's Hospital, providing AAV and lentiviral development and GMP manufacturing for gene therapy developers. Direct overlap in service portfolio, therapeutic modality, and customer segment.
• Genezen: Genezen is a US-based gene therapy CDMO offering AAV and lentiviral vector process development and cGMP manufacturing for early-stage gene therapy developers. Comparable niche focus, scale, and customer profile.
• Ascend Advanced Therapies: Ascend is a pure-play AAV and lentiviral CDMO offering process development, GMP manufacturing, and analytical services — closely mirroring DINAMIQS's core offering and target customer base of gene therapy developers.

Regional players

• Celonic Group: Celonic is a Swiss-German CDMO with expertise in viral vector and cell therapy manufacturing, overlapping with DINAMIQS in modality and Europe-focused operations but with a broader biologics service portfolio.

Broad incumbents

• Lonza Cell & Gene Technologies: Lonza is the largest global CDMO offering cell and gene therapy services including viral vector manufacturing, process development, and commercial supply. While broader in scope, it is a key competitor for large gene therapy manufacturing contracts.
• Catalent (Paragon Gene Therapy): Catalent acquired Paragon Gene Therapy, expanding into AAV viral vector manufacturing for gene therapy. A well-capitalized incumbent serving the same gene therapy customer segment, though within a much broader CDMO portfolio.
• Thermo Fisher Scientific (Viral Vector Services / Brammer Bio): Thermo Fisher's Viral Vector Services business, built on the Brammer Bio acquisition, offers viral vector development and GMP manufacturing for gene therapy developers. A large incumbent competing for the same commercial CDMO contracts.

Others

• SIRION Biotech: SIRION Biotech is a viral vector technology provider offering AAV and lentiviral vectors for cell and gene therapy applications. Though not a direct CDMO competitor, it is part of the same viral vector ecosystem and previously employed senior DINAMIQS business development leadership.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DINAMIQS